Content posted against Serum Institute of India prima facie defamatory: Bombay HC, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

The SII filed a defamation suit in December 2022 seeking damages to the tune of Rs 100 crore from the two individuals and their organisations for allegedly posting erroneous content against the company and its COVID-19 vaccine Covishield. The high court on Monday in its interim order said it was of the prima facie view that the SII has satisfied that the contents and accusations made by the two persons were defamatory., The SII filed a defamation suit in December 2022 seeking damages to the tune of Rs 100 crore from the two individuals and their organisations for allegedly posting erroneous content against the company and its COVID-19 vaccine Covishield. The high court on Monday in its interim order said it was of the prima facie view that the SII has satisfied that the contents and accusations made by the two persons were defamatory., , Read More